Literature DB >> 22395856

Epidemiology of neuropathic pain and its impact on quality of life.

Blair H Smith1, Nicola Torrance.   

Abstract

Epidemiology is an important clinical tool in designing and evaluating management and prevention strategies, and is particularly relevant to neuropathic pain. However, there is a relative lack of accurate information available. In one sense, neuropathic pain describes a symptom or a mechanism, rather than a specific disease; on the other hand, there are sufficient similarities in the effects and response to treatment between different causes to make it worthwhile to consider neuropathic pain as a distinct condition. However, there are important specific disease-based factors that need to be considered separately. Estimates of prevalence that are based on specific causes of neuropathic pain tend to be lower (1-2%) than those that are based on reports of the classic symptoms (6-8%), and further methodological research is needed. All neuropathic pain is associated with poor general health, comparable with other severe chronic diseases. The importance of newly proposed risk factors, including genetic factors, still needs to be assessed at a population level.

Entities:  

Mesh:

Year:  2012        PMID: 22395856     DOI: 10.1007/s11916-012-0256-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  62 in total

Review 1.  Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies.

Authors:  Per T Hansson; Anthony H Dickenson
Journal:  Pain       Date:  2005-02       Impact factor: 6.961

2.  Prevalence and risk factors of disk-related sciatica in an urban population in Tunisia.

Authors:  Mohamed Younes; Ismail Béjia; Zouhour Aguir; Mondher Letaief; Saoussen Hassen-Zrour; Mongi Touzi; Naceur Bergaoui
Journal:  Joint Bone Spine       Date:  2006-04-19       Impact factor: 4.929

Review 3.  New perspectives on the management of diabetic peripheral neuropathic pain.

Authors:  Troels S Jensen; Misha-Miroslav Backonja; Sergio Hernández Jiménez; Solomon Tesfaye; Paul Valensi; Dan Ziegler
Journal:  Diab Vasc Dis Res       Date:  2006-09       Impact factor: 3.291

4.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).

Authors:  Didier Bouhassira; Nadine Attal; Haiel Alchaar; François Boureau; Bruno Brochet; Jean Bruxelle; Gérard Cunin; Jacques Fermanian; Patrick Ginies; Aurélie Grun-Overdyking; Hélène Jafari-Schluep; Michel Lantéri-Minet; Bernard Laurent; Gérard Mick; Alain Serrie; Dominique Valade; Eric Vicaut
Journal:  Pain       Date:  2005-01-26       Impact factor: 6.961

Review 5.  Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

Authors:  Søren H Sindrup; Troels S Jensen
Journal:  Pain       Date:  1999-12       Impact factor: 6.961

6.  The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population.

Authors:  Barbara P Yawn; Peter C Wollan; Toby N Weingarten; James C Watson; W Michael Hooten; L Joseph Melton
Journal:  Pain Med       Date:  2009-03-17       Impact factor: 3.750

7.  Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community.

Authors:  Blair H Smith; Nicola Torrance; Michael I Bennett; Amanda J Lee
Journal:  Clin J Pain       Date:  2007-02       Impact factor: 3.442

8.  Effect of lingual nerve block on burning mouth syndrome (stomatodynia): a randomized crossover trial.

Authors:  Christelle Grémeau-Richard; Claude Dubray; Bruno Aublet-Cuvelier; Sylvie Ughetto; Alain Woda
Journal:  Pain       Date:  2010-01-18       Impact factor: 6.961

9.  A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.

Authors:  K Kieburtz; D Simpson; C Yiannoutsos; M B Max; C D Hall; R J Ellis; C M Marra; R McKendall; E Singer; G J Dal Pan; D B Clifford; T Tucker; B Cohen
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

Review 10.  The impact of neuropathic pain on health-related quality of life: review and implications.

Authors:  Mark P Jensen; Marci J Chodroff; Robert H Dworkin
Journal:  Neurology       Date:  2007-04-10       Impact factor: 9.910

View more
  76 in total

1.  The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Authors:  Lei Ding; Jie Cai; Xiang-Yang Guo; Xiu-Li Meng; Guo-Gang Xing
Journal:  Pain Res Manag       Date:  2014-05-21       Impact factor: 3.037

Review 2.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

3.  [Preoperative, neuropathic component in patients with back pain].

Authors:  Y-J Lee; E M W Koch; J B Breidebach; R Bornemann; D C Wirtz; R Pflugmacher
Journal:  Schmerz       Date:  2017-04       Impact factor: 1.107

4.  Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.

Authors:  Doralina L Anghelescu; Jessica Michala Tesney
Journal:  Paediatr Drugs       Date:  2019-04       Impact factor: 3.022

5.  Trachyspermum ammi 10 % topical cream versus placebo on neuropathic pain, a randomized, double-blind, placebo-controlled trial.

Authors:  Peyman Petramfar; Mahmoodreza Moein; Soliman Mohammadi Samani; Sayed Hamidreza Tabatabaei; Mohammad M Zarshenas
Journal:  Neurol Sci       Date:  2016-05-11       Impact factor: 3.307

6.  Intrathecal Administration of Tempol Reduces Chronic Constriction Injury-Induced Neuropathic Pain in Rats by Increasing SOD Activity and Inhibiting NGF Expression.

Authors:  Baisong Zhao; Yongying Pan; Zixin Wang; Yonghong Tan; Xingrong Song
Journal:  Cell Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.046

7.  Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy.

Authors:  Chaoling Dong; E Scott Helton; Ping Zhou; Xuan Ouyang; Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo; Eroboghene E Ubogu
Journal:  Tissue Barriers       Date:  2018-09-05

8.  The characteristics of chronic pain after non-traumatic, non-compressive myelopathy: Focus on neuropathic pain.

Authors:  Young In Eom; Min Kim; In Soo Joo
Journal:  J Spinal Cord Med       Date:  2016-08-31       Impact factor: 1.985

9.  Neuropathic Pain Among Community-Dwelling Older People: A Clinical Study in Finland.

Authors:  Susanna Rapo-Pylkkö; Maija Haanpää; Helena Liira
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

10.  Dendritic spine remodeling following early and late Rac1 inhibition after spinal cord injury: evidence for a pain biomarker.

Authors:  Peng Zhao; Myriam Hill; Shujun Liu; Lubin Chen; Lakshmi Bangalore; Stephen G Waxman; Andrew M Tan
Journal:  J Neurophysiol       Date:  2016-03-02       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.